NZ203428A - 1,2,4-triazines and pyrazines - Google Patents

1,2,4-triazines and pyrazines

Info

Publication number
NZ203428A
NZ203428A NZ203428A NZ20342883A NZ203428A NZ 203428 A NZ203428 A NZ 203428A NZ 203428 A NZ203428 A NZ 203428A NZ 20342883 A NZ20342883 A NZ 20342883A NZ 203428 A NZ203428 A NZ 203428A
Authority
NZ
New Zealand
Prior art keywords
compound
bis
methylphenyl
formula
triazin
Prior art date
Application number
NZ203428A
Other languages
English (en)
Inventor
D T Wong
W B Lacefield
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ203428A publication Critical patent/NZ203428A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/16Halogen atoms; Nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Enzymes And Modification Thereof (AREA)
NZ203428A 1982-03-05 1983-03-01 1,2,4-triazines and pyrazines NZ203428A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/354,982 US4513135A (en) 1982-03-05 1982-03-05 Diaryl-pyrazine derivatives affecting GABA binding

Publications (1)

Publication Number Publication Date
NZ203428A true NZ203428A (en) 1986-09-10

Family

ID=23395746

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ203428A NZ203428A (en) 1982-03-05 1983-03-01 1,2,4-triazines and pyrazines

Country Status (22)

Country Link
US (2) US4513135A (https=)
EP (1) EP0088593B1 (https=)
JP (1) JPS58162582A (https=)
KR (1) KR860000847B1 (https=)
AT (1) ATE27457T1 (https=)
AU (1) AU547581B2 (https=)
CA (1) CA1195327A (https=)
DD (1) DD207716A5 (https=)
DE (1) DE3371786D1 (https=)
DK (1) DK97283A (https=)
ES (2) ES520340A0 (https=)
FI (1) FI830708A7 (https=)
GB (1) GB2116179B (https=)
GR (1) GR78459B (https=)
HU (1) HU191368B (https=)
IL (1) IL68002A (https=)
NZ (1) NZ203428A (https=)
PH (1) PH22535A (https=)
PL (1) PL240871A1 (https=)
PT (1) PT76312B (https=)
RO (1) RO86320B (https=)
ZA (1) ZA831387B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (fr) * 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
WO1992002513A1 (en) * 1990-08-06 1992-02-20 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic compounds
GB9420010D0 (en) * 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
TWI316055B (https=) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
KR100490893B1 (ko) * 2002-10-11 2005-05-23 (주) 비엔씨바이오팜 2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
MX2007009224A (es) * 2005-02-01 2008-03-13 Lake Erie Products Sujetador para evitar el trasroscado.
TW200716594A (en) * 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド 5ht受容体介在性の神経新生
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2579949T3 (es) 2010-02-05 2016-08-17 Heptares Therapeutics Limited Derivados de 1,2,4-triazin-4-amina
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
AR088256A1 (es) * 2011-10-08 2014-05-21 Novartis Ag Derivados de carbamato / urea como antagonistas del receptor h3
EP4302834A3 (en) * 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
EP3549935A4 (en) * 2016-11-30 2020-08-05 Mitsubishi Tanabe Pharma Corporation TRIAZINE COMPOUND PRODUCTION PROCESS
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としての二環式化合物
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構shp2抑制劑的吡啶、吡嗪和三嗪化合物
JP7361693B2 (ja) 2017-12-15 2023-10-16 レヴォリューション・メディスンズ,インコーポレイテッド アロステリックshp2阻害剤としての多環式化合物
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
MX2020011565A (es) 2018-05-01 2021-01-29 Revolution Medicines Inc Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
CA3256390A1 (en) 2022-05-25 2023-11-30 Revolution Medicines, Inc. CANCER TREATMENT METHODS USING AN MTOR INHIBITOR
CN117304174B (zh) * 2022-06-20 2026-04-28 四川轻化工大学 一种5,6-二苯基吡嗪-2-氮杂环类化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172889A (en) * 1965-03-09 Process for the separation of z-methyl-
US3294638A (en) * 1961-06-05 1966-12-27 Warner Lambert Pharmaceutical Method and compositions employing 2-alkyl-3-piperidinopyrazines
CH480795A (de) * 1967-03-01 1969-11-15 Sandoz Ag Mittel zur Beeinflussung des Pflanzenwachstums
US4013654A (en) * 1974-01-31 1977-03-22 Eli Lilly And Company 5,6-diaryl-1,2,4-triazines
US3989831A (en) * 1974-01-31 1976-11-02 Eli Lilly And Company Topically-active anti-inflammatory 3-chloro-5,6-diaryl-1,2,4-triazines
US3979516A (en) * 1974-01-31 1976-09-07 Eli Lilly And Company Anti-inflammatory 3-amino-5,6-diaryl-1,2,4-triazines
US3948894A (en) * 1974-01-31 1976-04-06 Eli Lilly And Company 3-Amino-5,6-diaryl-1,2,4-triazines
US4081542A (en) * 1975-04-21 1978-03-28 Merck & Co., Inc. Piperazinylpyrazines
GB1493998A (en) * 1975-06-03 1977-12-07 Beecham Group Ltd Propanolamine derivatives
US4008232A (en) * 1975-06-23 1977-02-15 Eli Lilly And Company 3-Amino-5,6-diaryl-1,2,4-triazines
US4082844A (en) * 1976-02-09 1978-04-04 Merck & Co., Inc. 6-chloro-2-(1-piperazinyl)pyrazine
US4018923A (en) * 1976-03-10 1977-04-19 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
US4021553A (en) * 1976-03-10 1977-05-03 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
US4190725A (en) * 1976-03-10 1980-02-26 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines
DE2810052A1 (de) * 1977-03-09 1978-09-14 Fabre Sa Pierre Aminoaryl-1,2,4-triazine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
IL54728A (en) * 1977-05-17 1983-06-15 Diamond Shamrock Corp Substituted 1,2,4-triazines and pharmaceutical compositions containing them
US4251527A (en) * 1977-05-17 1981-02-17 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines
US4157392A (en) * 1977-05-17 1979-06-05 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines

Also Published As

Publication number Publication date
HU191368B (en) 1987-02-27
GB8305846D0 (en) 1983-04-07
ES8504173A1 (es) 1985-04-16
KR840004101A (ko) 1984-10-06
DK97283D0 (da) 1983-02-28
FI830708L (fi) 1983-09-06
ES8404346A1 (es) 1984-04-16
GB2116179A (en) 1983-09-21
IL68002A0 (en) 1983-06-15
EP0088593A2 (en) 1983-09-14
FI830708A0 (fi) 1983-03-02
ATE27457T1 (de) 1987-06-15
GB2116179B (en) 1985-09-11
US4585861A (en) 1986-04-29
JPS58162582A (ja) 1983-09-27
EP0088593B1 (en) 1987-05-27
ES520340A0 (es) 1984-04-16
GR78459B (https=) 1984-09-27
KR860000847B1 (ko) 1986-07-09
PL240871A1 (en) 1984-06-18
RO86320A (ro) 1985-03-15
DD207716A5 (de) 1984-03-14
IL68002A (en) 1986-09-30
PH22535A (en) 1988-10-17
CA1195327A (en) 1985-10-15
PT76312A (en) 1983-04-01
ES526297A0 (es) 1985-04-16
RO86320B (ro) 1985-03-31
ZA831387B (en) 1984-10-31
US4513135A (en) 1985-04-23
AU547581B2 (en) 1985-10-24
PT76312B (en) 1986-02-04
AU1202983A (en) 1983-09-08
DK97283A (da) 1983-09-06
DE3371786D1 (en) 1987-07-02
FI830708A7 (fi) 1983-09-06
EP0088593A3 (en) 1984-05-23

Similar Documents

Publication Publication Date Title
EP0088593B1 (en) 1,2,4-triazine and pyrazine derivatives
JP2756742B2 (ja) N−アシル−2,3−ベンゾジアゼピン誘導体、その製造法、それを含有する医薬組成物、およびその製造法
KR100292592B1 (ko) 세로토닌길항제로서의n-시아노n'-피리딜구아니딘
US3995039A (en) Pyrazolo [1,5-a] [1,3,5] triazines
US4244950A (en) Derivatives of 4-amino-3-sulfonamido-pyridine, their preparation and use
CZ99797A3 (en) Purine and guanine compounds as pnp inhibitors
JPH05132467A (ja) N−ビフエニルメチル置換二窒素複素環誘導体、製法および医薬組成物
KR20130046436A (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도
SK283536B6 (sk) Pyridylftalazindióny, spôsob ich prípravy a použitie a farmaceutické prostriedky na ich báze
AU781837B2 (en) 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity
EP0186817A1 (en) 3(2H)pyridazinone, process for its preparation and anti-allergic agent containing it
FR2701708A1 (fr) Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
JP5467044B2 (ja) Tsh受容体拮抗性のテトラヒドロキノリン化合物
AU759618B2 (en) Tan-1057 derivatives
JP2668163B2 (ja) コレステロール血症および抗アテローム動脈硬化症薬としての4−アリール−3−(ヘテロアリールウレイド)−1,2−ジヒドロ−2−オキソ−キノリン誘導体
SU1342415A3 (ru) Способ получени производных пиридазина
US4977152A (en) Novel tricyclic derivatives which are agonists of cholinergic receptors, and drugs in which they are present
DE69519315T2 (de) Aminoalkyl Benzoxazolinone und Benzothiazolinone, Verfahren zu deren Herstellung und sie enthaltende Zusammensetzungen
EP0269355B1 (en) Imidazolidinedione derivatives
HU218274B (en) N,n'-bis hydroxyalkyl and alkoxyalkyl-pyridine-2,4-dicarboxylic acid diamide derivatives and pharmaceutical compositions comprising such compounds and process for producing them
US3793326A (en) 3,4-dihydro-6,7-substituted-2,2,3-lower alkyl-4-oxo-(2h)-quinazolecarboxylic acid derivatives useful as analgesic and tranquilizer agents
US4292323A (en) Phenyl-1,2,3,4-tetrahydrocarbazoles and use thereof
CS229692B2 (en) Manufacturing process of derivate 4-phenylquinazoline
AU741162B2 (en) New 2,3-benzodiazepine derivatives
EP0663395B1 (de) 3-(Phenylalkylaminoalkyloxy)-5-phenylpyrazol-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung als herzfrequenzsenkendes Mittel